Faeth Therapeutics, Inc. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
Faeth Therapeutics, Inc. (FTH) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $100.00 thousand as of 2024-06-30, per its 10-Q filed 2024-08-06.
Discontinued › Notes
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2024-08-06
- 2024-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $100.00K.
- 2024-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $100.00K.
- 2023-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $200.00K.
- 2023-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $400.00K.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2024-06-30 | $100.00K 10-Q · filed 2024-08-06 |
| 2024-03-31 | $100.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $200.00K 10-K · filed 2024-02-29 |
| 2023-09-30 | $400.00K 10-Q · filed 2023-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |